Literature DB >> 2300172

Identification and isolation of a membrane protein necessary for leukotriene production.

D K Miller1, J W Gillard, P J Vickers, S Sadowski, C Léveillé, J A Mancini, P Charleson, R A Dixon, A W Ford-Hutchinson, R Fortin.   

Abstract

Several inflammatory diseases, including asthma, arthritis and psoriasis are associated with the production of leukotrienes by neutrophils, mast cells and macrophages. The initial enzymatic step in the formation of leukotrienes is the oxidation of arachidonic acid by 5-lipoxygenase (5-LO) to leukotriene A4. Osteosarcoma cells transfected with 5-LO express active enzyme in broken cell preparations, but no leukotriene metabolites are produced by these cells when stimulated with the calcium ionophore A23187, indicating that an additional component is necessary for cellular 5-LO activity. A new class of indole leukotriene inhibitor has been described that inhibits the formation of cellular leukotrienes but has no direct inhibitory effect on soluble 5-LO activity. We have now used these potent agents to identify and isolate a novel membrane protein of relative molecular mass 18,000 which is necessary for cellular leukotriene synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300172     DOI: 10.1038/343278a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  80 in total

Review 1.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

Review 2.  The organization and consequences of eicosanoid signaling.

Authors:  Roy J Soberman; Peter Christmas
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  The membrane organization of leukotriene synthesis.

Authors:  Asim K Mandal; Jesse Skoch; Brian J Bacskai; Bradley T Hyman; Peter Christmas; Douglas Miller; Ting-ting D Yamin; Shihua Xu; Douglas Wisniewski; Jilly F Evans; Roy J Soberman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

4.  The relationship between the polymorphism of SG13S114 A/T in ALOX5AP gene and the vulnerability of carotid atherosclerosis in Chinese Han population.

Authors:  Xiaoping Jin; Yinglei He; Min Zhu; Xianfang Lin; Qiuyue Chen; Zhao Han; Xiaoya Huang; Feng Wang
Journal:  Int J Clin Exp Med       Date:  2010-01-01

5.  How chemoproteomics can enable drug discovery and development.

Authors:  Raymond E Moellering; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2012-01-27

6.  COX-2-dependent and -independent biosynthesis of dihydroxy-arachidonic acids in activated human leukocytes.

Authors:  Noemi Tejera; William E Boeglin; Takashi Suzuki; Claus Schneider
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

7.  Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster.

Authors:  H A Lehr; A Guhlmann; D Nolte; D Keppler; K Messmer
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

8.  5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.

Authors:  René Hennig; Xian-Zhong Ding; Wei-Gang Tong; Matthias B Schneider; Jens Standop; Helmut Friess; Markus W Büchler; Parviz M Pour; Thomas E Adrian
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  The nuclear membrane organization of leukotriene synthesis.

Authors:  Asim K Mandal; Phillip B Jones; Angela M Bair; Peter Christmas; Douglas Miller; Ting-ting D Yamin; Douglas Wisniewski; John Menke; Jilly F Evans; Bradley T Hyman; Brian Bacskai; Mei Chen; David M Lee; Boris Nikolic; Roy J Soberman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.